Dernières nouvelles pour Hubbell (NYSE:HUBB) Stock

Hubbell

Founded in 1888 by Harvey Hubbell, the eponymous company was the conduit through which the pull-chain lamp socket was originally sold. Hubbell has since grown into an electricity transmission and distribution behemoth, housing more than 75 brands that sell components found on power lines, electrical substations, and within commercial and industrial buildings. The company's primary operations are within the United States, where around 90% of revenue is derived.

Hubbell Inc

Hubb Ventures Inc

Mastercard Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) is charting a new course for the digital economy, and it&#8217;s a future where open banking and stablecoins are at the core. This includes the potential for stablecoins to act as settlement currencies, as the company states it sees them as just another form of money.
Check out the <a href="https://www.benzinga.com/quote/MA">MA stock price over here</a>. 
What Happened: During its <a href="https://www.benzinga.com/markets/earnings/25/07/46760053/mastercard-stock-jumps-after-strong-q2-travel-spending-digital-services-fuel-revenue-beat-and-raised-outlook">earnings</a> call, executives underscored the company&#8217;s &#8220;Open banking&#8221; initiative as a key to future growth. This is a system that allows banks and other financial institutions to share customer financial data securely with third-party providers with the customer&#8217;s explicit consent. 
CEO Michael Mihwach underscored that one of the most notable open banking developments is the launch of &#8220;Mastercard Account to Account Protect,&#8221; a new fraud prevention service. A critical part of this &#8220;Mastercard One credential&#8221; is its ability to provide consumers with flexibility in how they pay, whether through debit, credit, prepaid, or even stablecoin. 
The <a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46729976/300-growth-in-high-inflation-nations-why-stablecoins-are-booming-where-fiat-is-failing">inclusion of stablecoins</a> as potential settlement currencies is a clear signal that Mastercard sees a future where it not only facilitates payments for traditional currency but for digital assets as well. &#8220;As to Stablecoins, we see it as another currency,&#8221; said Mihwach. 
&#8220;We will bring our reach, ubiquity, and trust to Agentic Commerce and Stablecoins and will provide an environment for our partners to innovate upon. That is the Mastercard way,&#8221; he added. 
Mastercard is leveraging this by enhancing fraud prevention, forging new partnerships, and creating a &#8220;global account overlay.&#8221; The company is also leveraging open banking to secure new partnerships and expand its market share globally.
The company also outlined its strategy about providing choice and partnering wherever possible. This is further evidenced by its work with Deutsche Bank AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DB#NYSE">DB</a>) to grow account-to-account payments across Europe.
The vision, as described by Mihwach, is to provide a single digitally connected credential that gives consumers flexibility in how they pay, whether through debit, credit, prepaid, or even stablecoin.
See Also: <a href="https://www.benzinga.com/markets/earnings/25/07/46748274/qualcomm-is-biggest-beneficiary-for-smart-glasses-powering-designs-for-meta-oakley-ray-ban-best-">Qualcomm Is &#8216;Biggest Beneficiary&#8217; For Smart Glasses—Powering Designs For Meta, Oakley, Ray-Ban: &#8216;Best One For Now,&#8217; Says Expert</a>
Why It Matters: The company <a href="https://www.benzinga.com/markets/earnings/25/07/46760053/mastercard-stock-jumps-after-strong-q2-travel-spending-digital-services-fuel-revenue-beat-and-raised-outlook">reported revenue</a> of $8.13 billion, up 17% year-over-year and 16% YoY on a neutral currency basis, beating the analyst consensus estimate of $7.95 billion. Its adjusted EPS rose 16% YoY to $4.15, exceeding the analyst consensus estimate of $4.02.
The company now expects high-end mid-teens revenue growth (prior low teen-digit revenue growth) for fiscal 2025 versus the $31.96 billion analyst consensus estimate.
Price Action: MA stock rose 1.32% on Thursday. The stock was up 8.44% year-to-date and 22.5% over a year. It was trading 0.61% lower in premarket on Friday. 
Benzinga's Edge Stock Rankings indicate that MA maintains a strong price trend across the short, medium, and long term. However, the stock scores badly on value rankings. Additional performance details are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-3/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-3/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="158" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01033250/MA-EDGE-1-1024x158.png" alt="" class="wp-image-1010316" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01033250/MA-EDGE-1-1024x158.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01033250/MA-EDGE-1-300x46.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01033250/MA-EDGE-1-768x118.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01033250/MA-EDGE-1.png 1290w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and&nbsp;Invesco QQQ Trust ETF&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, dropped in premarket on Friday. The SPY was down 0.94% at $626.13, while the QQQ declined 1.09% to $558.85, according to&nbsp;<a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>&nbsp;data.
On Friday, the futures of Dow Jones, S&amp;P 500, and Nasdaq 100 indices were trading lower.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/hedge-funds/25/07/46687204/warren-buffett-has-56-of-his-258-billion-portfolios-value-exposed-to-ai-here-are-the-5-stocks-that-are-leveraging-ai-within-berkshires-holdings" target="_blank" rel="noreferrer noopener">Warren Buffett Has 56% Of His $258 Billion Portfolio's Value Exposed To AI: Here Are The 5 Stocks That Are Leveraging AI Within Berkshire's Holdings</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo: rblfmr/Shutterstock

News

Mastercard To Enable Stablecoins As Settlement Currencies As It Touts Open Banking For Fraud Prevention: 'We See It As Another Currency'

Pheton Holdings Ltd (the "Company," "we," "our" or "Pheton"), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other related products and services, today issued the following statements in response to recent market volatility and a third-party publication that has raised questions and concerns among shareholders.
Over the past few days, shares of Pheton have experienced an extraordinary and unexpected decline in its share price, which the Company believes may have been triggered by a speculative article published by The Bear Cave on July 29, 2025. The article asserts that Pheton's share price may have been influenced by false rumors of a potential acquisition by Gilead Sciences, Inc. ("Gilead").
Management's Position and Clarification
Pheton's management team unequivocally and categorically denies any involvement in, or knowledge of, any form of stock price manipulation. At no point has the Company participated in, initiated, or sanctioned any rumor, communication, or activity regarding an acquisition by Gilead, or any other party. Pheton has had no contact with Gilead, and any statements or reports suggesting otherwise were and are entirely false and fabricated.
Additionally, Pheton plans to engage with its market makers, Nasdaq, and relevant regulatory bodies for the purpose of holding responsible parties to the scheme accountable.
Protecting Shareholder Interests
We recognize the concern this incident has caused among our investors, and we are monitoring internal controls and communications to ensure that any further misinformation can be swiftly and effectively countered.
Commitment to Transparency and Growth
Pheton is committed to upholding the highest standards of corporate governance, transparency, and accountability. As always, we remain focused on creating long-term shareholder value through carefully considered growth opportunities that align with our mission and strengthen our market position.
Pheton has built its foundation on trust, innovation, and value creation and remains confident in the strength of its underlying business, long-term strategy, and the dedication of its team.
A Word to Our Shareholders
We deeply value the trust our shareholders place in us. We will continue to keep the investor community informed with accurate and timely disclosures. Our leadership remains focused on operational execution and strengthening the integrity of our public market presence.

PTHL

Pheton Addresses Market Volatility Following Speculative Report Linking Company To Gilead Acquisition Rumors

Biotech

General

ALLO

Allogene Therapeutics FC Plus ALLO-647 Arm Closed Early Due To Grade 5 Adverse Event, Linked To ALLO-647, With Hepatic Failure From Adenovirus On Day 54

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Needham analyst Gerald Pascarelli initiated coverage on Turning Point Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPB#NYSE">TPB</a>) with a Hold rating. Turning Point Brands shares closed at $82.94 on Thursday. <a href="https://www.benzinga.com/quote/TPB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Luke Sergott initiated coverage on Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with an Overweight rating and announced a price target of $90. Incyte shares closed at $74.89 on Thursday. <a href="https://www.benzinga.com/quote/INCY/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying INCY stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="571" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092938/image-12-1024x571.png" alt="" class="wp-image-1010888" style="width:685px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092938/image-12-1024x571.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092938/image-12-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092938/image-12-768x428.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092938/image-12.png 1126w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/08/46790607/how-to-earn-500-a-month-from-oneok-stock-ahead-of-q2-earnings">How To Earn $500 A Month From ONEOK Stock Ahead Of Q2 Earnings</a></li>
</ul>
Photo via Shutterstock

Initiation

Markets

Analyst Ratings

Trading Ideas

INCY

This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday

WIIM

PSO stock has given up its prior loss. Pearson shares were trading lower after the company reported a year-over-year decrease in H1 financial results.

Macro Economic Events

Economics

Federal Reserve

Reuters Reporting Fed's Hammack Says Fed Sees Pressure On Inflation Side Of Mandate With Inflation Continuing To Influence Economic Decisions; Tariff Passthrough To Prices And Weakness In Job Market Into End Of Year

HOLX

HOLX stock has given up its prior gain. Hologic shares were trading higher after Morgan Stanley and UBS raised their respective price targets on the stock.

Raymond James analyst Melissa Fairbanks reiterates Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) with a Outperform and raises the price target from $720 to $875.

Price Target

Reiteration

MPWR

Raymond James Reiterates Outperform on Monolithic Power Systems, Raises Price Target to $875

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Baird analyst Shrenik Kothari downgraded the rating for CyberArk Software Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) from Outperform to Neutral and maintained the price target of $460. CyberArk Software shares closed at $411.47 on Thursday. <a href="https://www.benzinga.com/quote/cybr/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Lizzie Dove downgraded Avis Budget Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAR#NASDAQ">CAR</a>) from Neutral to Sell and raised the price target from $87 to $105. Avis Budget shares closed at $170.24 on Thursday. <a href="https://www.benzinga.com/quote/car/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Michael Ciarmoli downgraded Albany International Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIN#NYSE">AIN</a>) from Buy to Hold and slashed the price target from $70 to $55. Albany International shares closed at $54.19 on Thursday. <a href="https://www.benzinga.com/quote/ain/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst David Manthey downgraded Builders FirstSource, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) from Outperform to Neutral and cut the price target from $145 to $130. Builders FirstSource shares closed at $127.13 on Thursday. <a href="https://www.benzinga.com/quote/BLDR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Aaron Kimson downgraded Procore Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) from Market Outperform to Market Perform and maintained the price target of $95. Procore Technologies shares closed at $71.63 on Thursday. <a href="https://www.benzinga.com/quote/PCOR/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CYBR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/CYBR/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="591" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092510/image-11-1024x591.png" alt="" class="wp-image-1010876" style="width:596px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092510/image-11-1024x591.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092510/image-11-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092510/image-11-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01092510/image-11.png 1103w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/08/46790607/how-to-earn-500-a-month-from-oneok-stock-ahead-of-q2-earnings">How To Earn $500 A Month From ONEOK Stock Ahead Of Q2 Earnings</a></li>
</ul>
Photo via Shutterstock

Downgrades

BLDR

CYBR

PCOR

This CyberArk Software Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Raymond James analyst Frank Louthan maintains Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) with a Outperform and raises the price target from $4.5 to $5.

LUMN

Raymond James Maintains Outperform on Lumen Technologies, Raises Price Target to $5

Raymond James analyst Srini Pajjuri reiterates KLA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) with a Outperform and raises the price target from $850 to $950.

KLAC

Raymond James Reiterates Outperform on KLA, Raises Price Target to $950

Barclays analyst Brandt Montour maintains Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) with a Overweight and raises the price target from $25 to $31.

NCLH

Barclays Maintains Overweight on Norwegian Cruise Line, Raises Price Target to $31

Wedbush analyst Alicia Reese maintains Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Outperform and raises the price target from $142 to $165.

RBLX

Wedbush Maintains Outperform on Roblox, Raises Price Target to $165

On Friday,&nbsp;Regeneron Pharmaceuticals&nbsp;Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) reported second-quarter adjusted earnings of $12.89 per share, up 12% year-over-year, beating the&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus of $8.57</a>.
The&nbsp;company reported sales&nbsp;of $3.68 billion, up 4% year over year, beating the <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/08/46785919/regeneron-pharmaceuticals-likely-to-report-lower-q2-earnings-these-most-accura" rel="noreferrer noopener">consensus of $3.29 billion</a>.
In the second quarter, U.S. net sales for Eylea HD&nbsp;and Eylea&nbsp;decreased 25% year-over-year to $1.15&nbsp;billion, including $393 million from Eylea HD and $754 million from Eylea.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/06/45726872/regeneron-experimental-weight-loss-drug-with-novo-nordisks-wegovy-helps-preserve-lean-mass-in-mid-stage-study" rel="noreferrer noopener">Regeneron&#8217;s Obesity Trial With Novo Nordisk&#8217;s Wegovy Hits Lean Target</a>
Net product sales of Eylea HD increased in the second quarter of 2025, compared to the second quarter of 2024, due to higher sales volumes driven by increased demand.
Net product sales of EYLEA were negatively impacted by lower sales volumes due to continued competitive pressures, loss in market share to compounded bevacizumab due to patient affordability constraints, continued transition of patients to EYLEA HD, and a lower net selling price.
Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) collaboration revenue increased, due to the company&#8217;s share of profits from the commercialization of antibodies, which were $1.282 billion and $988&nbsp;million in the second quarter of 2025 and 2024, respectively.
The change in the company&#8217;s share of profits from the commercialization of antibodies was driven by higher profits associated with an increase in Dupixent sales.
<h2 class="wp-block-heading">Pipeline Update</h2>
In its earnings press release, Regeneron said it expects regulatory approvals to be delayed for its currently pending U.S. Food and Drug Administration (FDA) applications for EYLEA HD (pre-filled syringe, every-four-week dosing, and for macular edema following retinal vein occlusion), which have <a target="_blank" href="https://www.benzinga.com/pressreleases/25/08/g46788448/regeneron-reports-second-quarter-2025-financial-and-operating-results" rel="noreferrer noopener">PDUFA dates in August 2025</a>.
The anticipated delay concerns observations from an FDA general site inspection at the filler for EYLEA HD in these regulatory applications, Catalent Indiana LLC, recently acquired by Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>).
The inspection was completed in mid-July and was not specific to EYLEA HD. Novo has communicated with the FDA and expects to submit its response next week.
Based on the company&#8217;s review of the observations, Novo&#8217;s proposed response to the FDA, and the progress the company has made with alternate third-party fillers, the company anticipates an expeditious resolution of the filling issues for EYLEA HD.
The FDA issued a Complete Response Letter (CRL) for the application for odronextamab, a bispecific antibody targeting CD20 and CD3, in relapsed/refractory follicular lymphoma after two or more lines of systemic therapy, which was also impacted by the Catalent site inspection.
<h2 class="wp-block-heading">Outlook</h2>
Regeneron expects a 2025 GAAP gross margin of approximately 83%, compared to the <a href="https://www.benzinga.com/25/04/45079889/regeneron-pharmaceuticals-q1-earnings-falls-short-on-expectations-revises-2025-gross-margin-outlook" target="_blank" rel="noreferrer noopener">prior guidance of 83%–84%</a>.
The company expects an adjusted gross margin of approximately 86%, compared to the&nbsp;prior guidance of 86%–87%.
Price Action:&nbsp;REGN stock is trading higher by 3.77% to $566 premarket at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/08/46789863/amazon-post-earnings-decline-totally-wrong-says-analyst-as-ceo-points-out-aws-has-more-demand-than-we-have-capacity" target="_blank" rel="noreferrer noopener">Amazon Post-Earnings Decline &#8216;Totally Wrong,&#8217; Says Analyst As CEO Points Out AWS Has &#8216;More Demand Than We Have Capacity&#8217;</a></li>
</ul>
Photo by Marianne Campolongo via Shutterstock

Earnings

Large Cap

Guidance

Health Care

Movers

REGN

Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines

Barclays analyst Ross Sandler maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Overweight and raises the price target from $640 to $810.

Barclays Maintains Overweight on Meta Platforms, Raises Price Target to $810

Raymond James analyst Srini Pajjuir reiterates Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Outperform and raises the price target from $230 to $240.

AAPL

Raymond James Reiterates Outperform on Apple, Raises Price Target to $240

JMP Securities analyst Andrew Boone maintains Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Market Outperform and raises the price target from $180 to $225.

RDDT

JMP Securities Maintains Market Outperform on Reddit, Raises Price Target to $225

Barclays analyst Matthew Bouley maintains Masco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAS#NYSE">MAS</a>) with a Overweight and raises the price target from $77 to $78.

Barclays Maintains Overweight on Masco, Raises Price Target to $78

Raymond James analyst Ryan Deschner maintains Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Outperform and lowers the price target from $52 to $50.

APLS

Raymond James Maintains Outperform on Apellis Pharmaceuticals, Lowers Price Target to $50

<ul>
<li>UNH</li>
<li>AMZN</li>
<li>FIG</li>
<li>GLD</li>
<li>NVDA</li>
<li>RDDT</li>
<li>AAPL</li>
<li>TSLA</li>
<li>AMD</li>
<li>META</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Comments

Hubbell

Actualités

Dernières nouvelles pour Hubbell (NYSE:HUBB) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL